All In Biotech

Drug Trial Radar · NCT07620041

Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

A Phase 1 Study to Evaluate the C-QTc Interval of QLC5508, Compare the Pharmacokinetics of Two Different Formulations, and Assess Drug-Drug Interaction Potential in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jun 9, 2026

Primary completion

Dec 5, 2026

Study completion Feb 5, 2027

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A clinical trial of QLC5508 for advanced solid tumors The goal of this clinical trial is to learn if QLC5508 can be given safely to adults with advanced solid tumors. It will also learn how two different formulations of QLC5508 compare in the body, and whether other drugs affect QLC5508. The main questions it aims to answer are: Does a single injection of QLC5508 change the heart's electrical activity (QTc interval)? How do the test formulation and the reference formulation of QLC5508 compare in the body (pharmacokinetics)? Do other drugs (itraconazole, darolutamide, or rifampicin) change how the body processes QLC5508? Investigators will compare the test formulation to the reference formulation, and will also give QLC5508 together with itraconazole, darolutamide, or rifampicin to look for drug-drug interactions. Participants will: Receive QLC5508 by injection into a vein; Join one of three groups: two groups will receive both formulations of QLC5508 at different times (crossover) and also take rifampicin or itraconazole; the third group will take darolutamide with QLC5508; Have heart monitoring (Holter) during the first dose; Undergo regular blood tests, safety checks, and immunogenicity testing (to see if the body develops antibodies against QLC5508).

Conditions

  • Refractory or Relapsed Solid Tumors

Interventions

  • QLC5508 (Investigational Product / Formulation T)Drug

    Single intravenous (IV) infusion of QLC5508 for pharmacokinetic (PK) and C-QTc assessment in patients with advanced solid tumors.

  • QLC5508 (Reference Product / Formulation R)Drug

    Single IV infusion of QLC5508 for comparative PK evaluation against the investigational formulation.

  • ItraconazoleDrug

    Multiple oral doses of itraconazole capsules to evaluate the drug-drug interaction (DDI) potential via CYP3A4 inhibition.

  • DarolutamideDrug

    Multiple oral doses of darolutamide tablets to evaluate the drug-drug interaction (DDI) potential.

  • RifampicinDrug

    Single oral dose of rifampicin capsules to evaluate the DDI potential.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The correlation between the plasma concentration of the QLC5508 payload and the change from baseline in the QTc interval (ΔQTc) derived from the concentration-QTc (C-QTc) model.Time frame: Time Frame: From baseline to approximately Month 6
  2. Following a single intravenous injection of QLC5508 Formulation T (investigational product) versus Formulation R (reference product), the Cmax of QLC5508Time frame: From baseline to approximately Month 6
  3. TheAUC0-t of QLC5508 following single use or co-administration with itraconazoleTime frame: From baseline to approximately Month 6
  4. The AUC0-∞ of QLC5508 following single use or co-administration with darolutamideTime frame: From baseline to approximately Month 6
  5. The Tmax of QLC5508 following single use or co-administration with rifampicinTime frame: From baseline to approximately Month 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jilin Province Tumor Hospital

    Changchun, Jilin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.